Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07115043 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
A Phase 1 study of Non-Small Cell Lung Cancer and Melanoma, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 11
- Study locations
NCT07115043 is a Phase 1 study of Non-Small Cell Lung Cancer and Melanoma that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 60 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (91% lower). The trial reports 11 study locations across 6 states.
The verdict
NCT07115043, a Phase 1 study of Non-Small Cell Lung Cancer and Melanoma, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 11
- Study locations
Study Summary
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Conditions Studied
Interventions
- DRUG AZD6750
- DRUG rilvegostomig
Study Locations (11)
Other
- Research Site - East Melbourne
- Research Site - Chūōku
- Research Site - Kashiwa
- Research Site - Seoul
- Research Site - Seoul
Texas
- Research Site - Houston
- Research Site - San Antonio
Michigan
- Research Site - Grand Rapids
Missouri
- Research Site - St Louis
Pennsylvania
- Research Site - Pittsburgh
Virginia
- Research Site - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-07-29 |
| Est. Completion | 2029-10-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07115043
The ClinicalTrials.gov registry entry for NCT07115043 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (91% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 9 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which AZD6750 is the first listed.
NCT07115043 reports 11 study locations spanning 6 distinct geographic areas - top geographies include Other, Texas, Michigan.
Frequently Asked Questions
What is clinical trial NCT07115043 about?
NCT07115043 is a clinical study titled "A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors". A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
What is the current status of trial NCT07115043?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2025-07-29. Estimated completion is 2029-10-02.
What conditions does trial NCT07115043 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Renal Cell Carcinoma, Triple Negative Breast Cancer.
What interventions are being tested in trial NCT07115043?
The interventions under investigation include: AZD6750 (DRUG), rilvegostomig (DRUG).
Who is sponsoring clinical trial NCT07115043?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07115043 being conducted?
This trial has 11 study locations across Michigan, Missouri, Pennsylvania, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.